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Background: Hops are the main components of beer that provide flavor and bitterness. Iso-α-acids, the bitter
components of beer, have been reported to reduce body fat in humans, but the bitterness induced by effective
doses of iso-α-acids precludes their acceptance as a nutrient. The matured hop bitter acids (MHBA) of oxidized
hops appear to have a more pleasant bitterness compared to the sharper bitterness of iso-α-acids. While there has
been little information concerning the identity of the MHBA compounds and their physiological effects, MHBA was
recently found to be primarily composed of oxides derived from α-acids, and structurally similar to iso-α-acids. Here,
we investigated the effects of matured hop extract (MHE) containing MHBA on reducing abdominal body fat in
healthy subjects with a body mass index (BMI) of 25 to below 30 kg/m2, classified as “obese level 1” in Japan or as
“overweight” by the WHO.
Trial design: A randomized, double-blind, placebo-controlled parallel group study.
Methods: Two hundred subjects (male and female aged 20 to below 65 years with a BMI of 25 or more and less
than 30 kg/m2) were randomly assigned to two groups. During a 12-week ingestion period, the subjects in each
group ingested daily 350 mL of test-beverage, either containing MHE (with 35 mg MHBA), i.e. the namely active
beverage, or a placebo beverage without MHE. The primary endpoint was reduction of the abdominal fat area as
determined by CT scanning after continual ingestion of MHE for 12 weeks.
Results: Compared to the placebo group, a significant reduction was observed in the visceral fat area after 8 and
12 w, and in the total fat area after 12 w in the active group. There was also a concomitant decrease in body fat
ratio in the active group compared to the placebo group. No adverse events related to the test beverages or
clinically relevant abnormal changes in the circulatory, blood and urine parameters were observed in either group.
Conclusions: The present study suggests that continual ingestion of MHE safely reduces body fat, particularly the
abdominal visceral fat of healthy overweight subjects.
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Obesity increases the risk of metabolic disorders, such
as insulin resistance, hyperlipidemia and hypertension,
which are risk factors of cardiovascular disease [1–3].
Because excess energy intake is a key cause of obesity,
suppression of energy intake and increase of energy ex-
penditure are obvious therapeutic approaches. Since the
prevalence of obesity is rapidly increasing around the
world, intensive research has been conducted into the
development of drugs and functional foods which can
prevent obesity. Indeed, some natural products have
been reported to decrease body fat in humans, while for
others there is little clinical evidence to demonstrate
their anti-obesity effect [4, 5].
Hops, the immature inflorescences of the female hop
plant (Humulus lupulus L.), have been widely used to
add flavor and bitterness to beer. Iso-α-acids, major bit-
ter components in beer, are converted from α-acids in
hops by isomerization during the brewing process [6],
and have been reported to have many health benefits
[7–9]. Among these, iso-α-acids were shown to prevent
obesity in mice and humans [10, 11]. However, it is diffi-
cult to add an effective dose of iso-α-acids to foods be-
cause of their bitterness. Interestingly, during storage the
α- and β-acid content in hops decreases, and other bit-
tering components accumulate [12]. There is little infor-
mation concerning the identity of these compounds
mainly because of their structural complexity and diffi-
culty in handling. Recently, it has been found that these
components, called matured hop bitter acids (MHBA),
primarily consist of α-acid oxides, which possess a com-
mon β-tricarbonyl moiety in their structures similar to
α-, β- and iso-α-acids [13–16]. In addition, a recent
study suggested that the oxidation products of α-acids
may result in a more pleasant tasting bitterness com-
pared to the sharper bitterness of iso-α-acids [17]. On
the basis of these findings, MHBA may be more useful
for food applications compared to iso-α-acids.
It has also been reported that MHBA ameliorates diet-
induced body fat accumulation in rodents by enhancing
thermogenesis in brown adipose tissue (BAT) via sym-
pathetic nerve activity innervating BAT [18]. BAT is a
major organ for cold- and diet-induced adaptive thermo-
genesis [19]. It has long been thought that BAT is abun-
dant in rodents, but absent or negligible in adult
humans. However, recent studies using fluorodeoxyglu-
cose positron emission tomography (FDG-PET) in com-
bination with computed tomography (CT) revealed that
adult humans have metabolically active BAT [20]. The
prevalence and activity of BAT in the human body are
inversely related to body fat content [21]. These studies
suggest that regulation of BAT activity is a possible
therapeutic target for obesity in humans. Thus, it might
be expected that MHBA reduces body fat in humans,however, there is no clinical evidence to support these
effects of MHBA in humans. To examine the effects of
MHBA on reducing body fat in humans, we prepared
matured hop extract (MHE), a hot water extract from
oxidized hops, which includes 18.3% of MHBA and un-
detectable amounts of α-, β- and iso-α-acids, in the solid
content.
In this study, we investigated the effects of 12-week in-
gestion of MHE on body fat reduction in healthy sub-
jects with a BMI of 25 or more and less than 30 kg/m2
by a randomized, double-blind, placebo-controlled paral-




The protocol (Protocol No. 26920) was approved by the
Institutional Review Boards of Ueno Clinic, Aiseikai
Public Interest Incorporated Foundation (Tokyo, Japan)
and Kensyokai Medical Corporation (Osaka, Japan) in
accordance with the ethical standards established in the
Helsinki Declaration and the ethical guidelines for epi-
demiological research of the Ministry of Education, Cul-
ture, Sports, Science and Technology, and the Ministry
of Health, Labor and Welfare of Japan. This study was
registered with the UMIN Clinical Trials Registry as
UMIN000014185 (Title; Study of effects of food contain-
ing hop extract on reducing body fat), and was conducted
in compliance with the protocol. Written informed con-
sent was obtained from all subjects. This study was per-
formed by a contract research organization, TTC Co., Ltd.
(Tokyo, Japan) from May 2014 to December 2014 at the
following three facilities: Ueno Clinic, Aiseikai Public
Interest Incorporated Foundation (Tokyo, Japan), Shinjyuku
Oiwake Clinic, Seikokai Medical Corporation (Tokyo,
Japan), and Fukushima Healthcare Center, Kensyokai
Medical Corporation (Osaka, Japan).
Subjects
The subjects were male and female aged 20 to below 65
years with a BMI of 25 or more and less than 30 kg/m2.
A BMI of 25 to below 30 kg/m2 is defined as “obese
(level 1)” by the Japan Society for the Study of Obesity
and as “overweight” by the WHO. The exclusion criteria
were as follows: on a diet; use of oral medication affect-
ing body fat or lipid metabolism; constant use of dietary
supplements or functional foods affecting body fat or
lipid metabolism; constant ingestion of foods enriched
with hop constituents; excessive alcohol-drinking behav-
ior; under treatment; onset of possible allergy symptoms;
with a history of serious disease (e.g., diabetes, liver dis-
ease, kidney disease or heart disease), thyroid gland dis-
ease, adrenal gland disease, or other metabolic disorder;
with severe anemia; with a history of digestive disease
Table 1 Nutritional compositions of test beverages (per 100 mL)
Active beverage Placebo beverage
Energy (kcal) 4.6 4.2
Protein (g) ND ND
Lipid (g) ND ND




MHE (mg, as the amount of MHBA) 10 0
ND, not detectable
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with a history of drug addiction or alcoholism; pos-
sible pregnancy, pregnancy or lactating; unfavorable
results of the given lifestyle questionnaire or blood
test; participation in a clinical study within the last
month prior to this study or possible participation in
another clinical study; donation of over 200 mL of
blood or blood component within the last month
prior to this study or over 400 mL of blood or blood
component within the last three months prior to this
study; any other reason for ineligibility as judged by
the site investigators.Target sample size
Based on a preliminary human study, MHE (with 35 mg
MHBA) was expected to reduce body fat by 5.8 cm2 with
a standard deviation of 12.1 cm2 compared to the pla-
cebo group. Setting the significance level at 5% by an
unpaired Student's t-test and the power at 0.85, the
number of subjects required per group was estimated to
be 80. To account for an expected dropout rate of 20%,
the number of subjects required per group was esti-
mated to be 100.Preparation of MHE
Hop pellets were purchased from HopSteiner (Mainburg,
Germany). Tricyclooxyisohumulones A was prepared as
described [14]. Hop pellets (300 g) were stored at 60°C for
120 h to oxidize α- and β-acids and then extracted with
pre-warmed H2O (50°C, 3 L) for 1 h. During extraction,
the temperature of the extract was maintained at 50°C.
The extract was filtered to remove the debris and then
treated with activated charcoal and PVPP for 2 h at room
temperature. After treatment, the mixture was filtered to
separate the extract from activated charcoal and PVPP.
After concentration to 11-12° Brix, the filtrate was heated
to 90°C for 4 h and then cooled to room temperature to
yield a pale brown liquid (450 g) referred to as MHE.
MHE contains 12% solid content, which consists for
18.3% of MHBA according to HPLC analysis using a pre-
viously reported method, while the amounts of α-, β- and
iso-α-acids were undetectable [16].Test beverages
We prepared 350 mL of test beverages, either containing
MHE (with 35 mg MHBA) in the case of the active bev-
erage, or without MHE for use as the placebo. The nu-
tritional composition of the test beverages is shown in
Table 1. The controller confirmed that there were no
discernible differences between the appearance and taste
of the two test beverages, and a record was kept before
allocation and at the blind broken.Study design
A randomized, double-blind, placebo-controlled parallel
group study was conducted over 18 weeks, consisting of
a 2-week pre-ingestion period (−2 to 0 w), a 12-week
test beverage ingestion period (0 to 12 w), and a 4-week
follow-up period without test beverage ingestion (12 to
16 w). Subjects were screened for eligibility over the 2
weeks preceding the ingestion period, and visited at 0, 4,
8, 12 and 16 w for the test. Interview, measurement of
anthropometric and circulatory parameters, blood sam-
pling, and urine sampling were conducted at each test.
CT scanning was performed at 0, 8, 12 and 16 w. Only
at the screening test, a lifestyle questionnaire was an-
swered by all subjects, and a pregnancy test was taken
by the female subjects.
The controller randomly assigned the subjects in a 1:
1 ratio to two groups with random numbers, and stored
an assignment list in a sealed container until database
lock. Throughout the study, the subjects, all investiga-
tors and study personnel except for the controller
remained blinded. During the ingestion period each sub-
ject took a test beverage 1 time per day. The time of test
beverage ingestion was not limited except on test days,
when subjects ingested the test beverage after the test
was completed. Subjects were instructed to continue
their usual eating, exercise, sleeping, smoking and drink-
ing habits, and to avoid overdrinking throughout the
study. Use of oral medication, dietary supplements and
functional foods affecting body fat or lipid metabolism,
and foods enriched with hop constituents were prohib-
ited. On the day before a test, subjects were prohibited
drinking alcohol and had to finish their evening meal by
22:00. Since then, eating and drinking (except for water)
were prohibited until the test on the following day was
completed. On the test day itself, smoking was prohib-
ited until the test was completed.
Discontinuance criteria of the study for the subjects
were as follows: risk of the subject′s safety; difficulty of
continuation of the study due to a serious adverse event
or accident; continuous or serious non-compliance with
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for discontinuation as judged by the site investigators.
Measurements of anthropometric and circulatory
parameters
Height was measured only at the screening test. Body
weight, body fat ratio, waist circumference, hip circum-
ference, systolic blood pressure (SBP), diastolic blood
pressure (DBP) and pulse rate were measured at each
test. The BMI was calculated from height and body
weight, and the ratio of waist to hip circumferences was
calculated. Blood pressure was measured once after a
5-min rest with the subject in the sitting position. The
body fat ratio was measured by bioelectrical impedance
analysis (BIA) using an Inner Scan 50V BC-621 (Tanita,
Tokyo, Japan). Inner Scan 50V BC-621 is a single-
frequency BIA device that uses eight polar electrodes
and is based on reactance technology, a method that
measures the body fat ratio more accurately than the
conventional BIA method by adopting reactance values
in addition to impedance values. An algorithm incorp-
orating impedance, age and height is used to estimate
the body fat ratio. The body fat ratio measured by the
BIA system with eight polar electrodes has been re-
ported to correlate with that measured by the dual en-
ergy X-ray absorptiometry (DXA) method [22].
Measurement of abdominal fat areas
The subjects underwent CT scanning of the abdominal
transverse section at the umbilical position using a
Robusto-Ei (Hitachi Medico, Tokyo, Japan) in Shinjyuku
Oiwake Clinic and an Asteion Super4 Edition TSX-021B
(Toshiba Medical Systems, Tochigi, Japan) in the
Fukushima Healthcare Center. The visceral fat area
(VFA), subcutaneous fat area (SFA) and total fat area
(TFA) were calculated from CT image using fatPointer
software (Hitachi Medico) in the Shinjyuku Oiwake Clinic
and SlimVision5 software (Cybernet Systems, Tokyo,
Japan) in the Fukushima Healthcare Center.
Blood chemistry and hematological examinations
The concentrations of the following parameters were
measured in fasting blood samples: total protein (TP),
albumin (Alb), total bilirubin (T-Bil), aspartate amino-
transferase (AST), alanine aminotransferase (ALT), lac-
tate dehydrogenase (LDH), alkaline phosphatase (ALP),
γ-glutamyl transpeptidase (γ-GTP), total cholesterol
(TC), low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), triglyceride
(TG), phospholipid (PL), free fatty acid (FFA), glucose,
uric acid (UA), blood urea nitrogen (BUN), creatinine
(Cre), sodium (Na), chloride (Cl), potassium (K), calcium
(Ca), magnesium (Mg), iron (Fe), total iron-binding cap-
acity (TIBC), unsaturated iron-binding capacity (UIBC)and ferritin for blood chemistry; and white blood cell
count (WBC), red blood cell count (RBC), hemoglobin
(Hb), hematocrit (Ht) and platelet count (Plt) for
hematology. All blood analyses were performed by a com-
mercial clinical laboratory (BML, Inc., Tokyo, Japan) using
the automatic analyzers LABOSPECT008K (Hitachi
High-Technologies, Tokyo, Japan) for blood chemistry
and XE-5000 (Sysmex, Hyogo, Japan) for hematology.
Urinalysis
Qualitative urinalyses of protein, glucose, occult blood,
urobilinogen and keton bodies were performed using
fasting urine samples. Urine pH was also measured. All
urinalyses were performed by BML, Inc. using the
automatic analyzer AX-4280 (Arkray, Kyoto, Japan).
Record of diet and physical activity, and daily life diary
Subjects recorded the contents of their daily meals,
snacks and beverages except for water, as well as the
number of steps taken by pedometer, on a paper record
of dietary and physical activity for three days before each
test at 0, 4, 8, 12 and 16 w. Daily average values for diet-
ary composition (energy, protein, fat, carbohydrate and
dietary fiber) were determined from the dietary record
using Calorie Checker version 5 (Healthcare Total
Solutions, Tokyo, Japan) by a nutritionist, and daily
average number of steps taken was calculated as physical
activity. The subjects also recorded the test beverage in-
gestion, subjective symptoms, and daily activities, includ-
ing eating habits, exercise habits, alcohol intake and drug
intake in the diary every day.
Interview
A physician interviewed the subjects about their physical
condition and subjective symptoms.
Endpoints
As determined before the beginning of the study, the pri-
mary endpoint was reduction of the abdominal fat area
after continual ingestion of the active beverage for 12
weeks, and secondary endpoints were a decrease of body
weight, BMI, body fat ratio, waist circumference and hip
circumference. Safety endpoints were occurrence of ad-
verse events and clinical laboratory parameters (body
weight, circulatory parameters, blood chemistry parame-
ters, hematological parameters, and urinalysis parameters).
When an adverse event occurred, the site investigators
conducted a follow-up survey until disappearance of the
symptoms or a trend of recovery from the event had set in
(Last date of the follow-up survey: December 8, 2014).
Statistical analysis
Data were expressed as the means (SEM). A paired
Student′s t-test was used to evaluate for each group
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began (0 w), and an unpaired Student′s t-test was used
to compare differences between the two groups at each
test point. In addition, for primary and secondary end-
points, the effects of two factors (time and group) and
a time-by-group interaction were analyzed by two-way
analysis of variance (ANOVA) using values obtained
during the test-beverage ingestion period. Differences
were considered significant at P < 0.05. All statistical
analyses were performed using PASW statics 18 (IBM,
Armonk, NY) or Microsoft Excel 2010 (Microsoft,
Redmond, WA).
Results
Background of the subjects
The subjects were recruited from April 28, 2014 to June
8, 2014. The disposition of the subjects enrolled in thisFig. 1 Flow diagram of the progress stages of this studystudy is shown in Fig. 1. Excluding 311 of the 511 partic-
ipants in the screening test in accordance with the inclu-
sion and exclusion criteria, 200 subjects (male = 100,
female = 100) were judged eligible by the site investiga-
tors, and were randomized into the active and the pla-
cebo group (100 subjects per group). Twelve subjects
dropped out of the study because of personal problems
not related to the study. In accordance with the exclu-
sion criteria, among the 188 remaining subjects who fin-
ished the study (94 subjects in each group), 10 subjects
were excluded from primary and secondary endpoint
evaluation by the site investigators before release of the
double-blind due to their failure to obey compliance
rules (five subjects) or because of a significant change of
life style that affected the study (five subjects). Conse-
quently, the statistical analyses for primary and second-
ary endpoint evaluation were conducted on 178 subjects
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placebo group). The baseline characteristics of the sub-
jects measured at the screening test are shown in Table 2.
No significant differences were found for any parameter
before the two groups were given the test beverages.
Average intake rates of test beverages during the inges-
tion period in the active group and the placebo group
were 99.0 ± 2.2% and 99.0 ± 2.1%, respectively. Table 3
shows daily average values for parameters linked to diet-
ary composition and physical activity. There were no sig-
nificant differences between the two groups in any of
these parameters throughout the study, although the
daily average energy intake and dietary fiber in the active
group appeared to be significantly decreased after, re-
spectively, 16 w and 4 w of test-beverage ingestion.
Primary endpoint
Figure 2 shows the change from the value at 0 w in vis-
ceral, subcutaneous and total abdominal fat areas during
the course of test-beverage ingestion (0 to 12 w) and
follow-up (12 to 16 w). VFA and TFA had decreased sig-
nificantly after 12 and 16 w in both groups but were sig-
nificantly lower in the active group than in the placebo
group after 8 w (VFA) and 12 w (VFA, TFA) (P < 0.05 at
each point for each parameter). No significant difference
in SFA was observed between the two groups, although
SFA was significantly decreased after 8, 12 and 16 w in
the placebo group, and after 12 and 16 w in the active
group. Two-way ANOVA indicated a significant effect of
group on VFA, significant effects of time on VFA, TFA
and SFA, and no significant time-by-group interaction
for any parameters during the test-beverage ingestion
period. There were no significant differences between
the two groups for each of the three abdominal fat areas
when test-beverage ingestion began (0 w).
Secondary endpoints
Table 4 shows the change in secondary endpoints since
the start of test-beverage ingestion (0 w). AlthoughTable 2 Baseline characteristics of the subjects
Parameter Active group Placebo group
n 91 87
Age (years) 44.8 (1.2) 44.1 (1.2)
Height (cm) 164.36 (0.93) 164.18 (0.90)
Body weight (kg) 74.65 (0.88) 74.42 (0.87)
BMI (kg/m2) 27.57 (0.13) 27.54 (0.12)
Body fat ratio (%) 32.12 (0.79) 32.15 (0.78)
Waist circumference (cm) 94.15 (0.55) 93.19 (0.52)
Hip circumference (cm) 101.09 (0.45) 101.08 (0.40)
Waist/Hip 0.932 (0.005) 0.922 (0.004)
Data are expressed as means (SEM). No significant differences were observed
in any parameters between the two groupssecondary endpoints for either group were not signifi-
cantly different at the beginning (data not shown), the
body fat ratio in the active group after 4, 8 and 12 w was
slightly but significantly lower than in the placebo group
(P < 0.05 at each point). Body weight and BMI were sig-
nificantly lower in the active group after 4 w (P < 0.01
for each parameter), and tended to be lower after 12 w
(P = 0.0697 for body weight and P = 0.0644 for BMI),
than in the placebo group. Body weight and BMI were
significantly decreased after 4, 12 and 16 w since the
start of test-beverage ingestion (0 w) in the active group,
while no significant variations were observed in the pla-
cebo group. In addition, waist circumference and hip cir-
cumference were significantly lower in the active group
after 4 w than the placebo group (P < 0.05 for each par-
ameter). Two-way ANOVA indicated significant effects
of group on body weight, BMI and body fat ratio, signifi-
cant effects of time on waist circumference, hip circum-
ference and the ratio of waist to hip circumferences, and
no significant time-by-group interaction for any parame-
ters during the test-beverage ingestion period.
Safety endpoints
Safety endpoint evaluation was conducted on 200 sub-
jects who ingested test beverages at least once (The stat-
istical analyses of parameters for safety endpoint
evaluation were conducted on 188 subjects who finished
the study.). Table 5 shows the result of circulatory par-
ameter measurement. SBP was significantly increased
after 16 w compared to the begin value (0 w) in the pla-
cebo group. DBP showed no significant variation from
the start value (0 w) in both groups throughout the
study. There was a significant difference in pulse rate be-
tween the two groups after 8, 12 and 16 w, while the
only significant variation from the start value (0 w)
within a group was observed after 4 w for the active
group: an increase which was not sustained. Comparison
of the analysis set for safety endpoint evaluation, with
that for secondary endpoint evaluation showed the same
body weight variation (data not shown). Body weight
and values of all circulatory parameters were within the
range of physiological variation.
Tables 6, 7, 8 and 9 show the result of blood chemistry
examination. γ-GTP (male), PL, UA (male and female),
Cl, Fe (male), UIBC (female) and ferritin (male and fe-
male) showed no significant variations from the start
values (0 w) in both groups and no significant differ-
ences between the two groups. Na and Fe (female)
showed significant differences between the two groups,
while there were no significant variations from the begin
values (0 w) in both groups. TP, Alb, T-Bil, AST, ALT,
LDH, ALP, γ-GTP (female), TC, LDL-C, HDL-C (male
and female), TG, FFA, glucose, BUN, Cre (male and
female), K, Ca, Mg, TIBC (male and female) and UIBC
Table 3 Dietary composition and physical activity
Parameter Group Ingestion period Follow-up period
0 w 4 w 8 w 12 w 16 w
Energy (kcal/day) A 1810.1 (50.9) 1821.2 (48.9) 1756.8 (44.3) 1774.2 (42.8) 1728.5 (46.3)*
P 1795.2 (38.3) 1781.6 (48.9) 1782.0 (43.9) 1803.5 (42.8) 1769.7 (45.7)
Protein (g/day) A 64.07 (1.98) 65.28 (2.06) 63.26 (1.71) 65.25 (1.70) 62.30 (1.99)
P 63.63 (1.67) 63.51 (2.10) 64.71 (1.85) 64.09 (1.66) 65.13 (2.07)
Fat (g/day) A 62.03 (2.12) 65.66 (2.19) 62.45 (2.36) 63.36 (1.94) 59.14 (2.30)
P 65.00 (2.06) 62.53 (2.19) 62.88 (2.02) 64.12 (2.06) 61.73 (2.25)
Carbohydrate (g/day) A 230.67 (7.68) 226.91 (6.70) 221.19 (6.11) 225.10 (6.10) 222.73 (5.89)
P 224.22 (5.60) 226.64 (6.47) 226.43 (6.17) 227.42 (5.47) 225.02 (5.78)
Dietary fiber (g/day) A 10.79 (0.47) 9.98 (0.34)* 10.41 (0.40) 10.50 (0.42) 10.40 (0.48)
P 10.56 (0.37) 9.84 (0.43) 10.26 (0.42) 10.37 (0.39) 10.67 (0.44)
Pedometer count (steps/day) A 7766.4 (410.2) 8098.6 (436.2) 7799.5 (403.3) 8011.9 (398.5) 7980.5 (397.2)
P 8350.7 (387.4) 8192.9 (403.5) 8254.4 (350.1) 8094.8 (350.2) 8089.6 (348.7)
Data are expressed as means (SEM). A, Active group (n = 91); P, Placebo group (n = 87). *P < 0.05 vs. 0 w
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values (0 w) in either group, while there were no signifi-
cant differences between the two groups at any point ex-
cept for the start value (0 w). Values of all blood chemistry
parameters were within reference ranges.
Table 10 shows the result of hematological examin-
ation. WBC, RBC (male and female), Hb (male and fe-
male), Ht (male and female) and Plt showed somea
c
b
Fig. 2 Effects of MHE on abdominal fat areas. Change in VFA (a), TFA
(b) and SFA (c). Data are calculated as the degrees of change from the
start values at 0 w (Δ), and expressed as means (SEM). *P < 0.05,
**P < 0.01 vs. 0 w (by paired Student’s t-test), #P < 0.05 vs. placebo
group (by unpaired Student’s t-test). A, Active group (n = 91); P, Placebo
group (n = 87). There was a significant effect of group (‡P < 0.01),
and of time (§P < 0.01) during the test-beverage ingestion period
(by two-way ANOVA)significant variations from the begin values (0 w) in ei-
ther group, but there were no significant differences be-
tween the two groups at any point except for 0 w.
Values of all hematological parameters were within refer-
ence ranges.
No clinically problematic findings were noted in urin-
alysis throughout the study, whereas urine pH was sig-
nificantly decreased after 8 w compared to the start
value (0 w) in the placebo group within the reference
range (Table 11).
During the study period, 83 cases divided over 47 sub-
jects in the active group and 78 cases for 43 subjects in
the placebo group were reported as adverse events. Of
both groups, the most common adverse event reported
related to cold-like symptoms. All adverse events are
shown in the Additional file 1. All cases were judged by
the site investigators to be mild and to have no relation
to the test beverages.
Discussion
In this study, we investigated the effect of continual
MHE ingestion for 12 weeks on reducing body fat in
healthy subjects with a BMI of 25 or more and less than
30 kg/m2 by an intervention trial without changing their
usual lifestyle. Our results show that VFA was signifi-
cantly decreased in the active group compared to the
placebo group after 8 and 12 w. In addition, TFA was
also significantly decreased in the active group after 12
w compared to the placebo group. In accordance with
the change in abdominal fat area, the body fat ratio was
slightly but significantly decreased in the active group
compared to the placebo group.
The subjects were instructed to keep their usual eat-
ing, exercise, sleeping, smoking, and drinking habits,
during the study period. Indeed, energy intake and
Table 4 Effect of MHE on body indices
Parameter Group Change from the value at 0 w
Ingestion period Follow-up period
4 w 8 w 12 w 16 w
ΔBody weight† (kg) A −0.30 (0.10)##,** −0.21 (0.12) −0.47 (0.17)** −0.51 (0.18)**
P 0.16 (0.10) 0.07 (0.17) −0.02 (0.18) 0.00 (0.21)
ΔBMI † (kg/m2) A −0.11 (0.04)##,** −0.08 (0.04) −0.17 (0.06)** −0.19 (0.07)**
P 0.06 (0.04) 0.02 (0.06) −0.01 (0.07) 0.00 (0.08)
ΔBody fat ratio † (%) A −0.29 (0.13)#,* −0.20 (0.15)# −0.10 (0.16)# −0.16 (0.17)
P 0.23 (0.17) 0.28 (0.15) 0.41 (0.20)* 0.34 (0.20)
ΔWaist circumference § (cm) A −0.52 (0.14)#,** −0.62 (0.17)** −0.97 (0.22)** −1.17 (0.23)**
P −0.10 (0.10) −0.26 (0.15) −0.58 (0.18)** −0.54 (0.27)*
ΔHip circumference § (cm) A −0.38 (0.10)#,** −0.50 (0.11)** −0.69 (0.14)** −0.81 (0.19)**
P −0.12 (0.08) −0.36 (0.12)** −0.46 (0.14)** −0.48 (0.15)**
ΔWaist/Hip § A −0.002 (0.001) −0.002 (0.001) −0.003 (0.002) −0.004 (0.002)
P 0.000 (0.001) 0.001 (0.001) −0.002 (0.001) −0.001 (0.002)
Data are calculated as the degrees of change from the values at 0 w (Δ), and expressed as means (SEM). A, Active group (n = 91); P, Placebo group (n = 87).
#P < 0.05, ##P < 0.01 vs. Placebo group. *P < 0.05, **P < 0.01 vs. 0 w. There was a significant effect of group (†P < 0.05), and of time (§P < 0.01) during the test-beverage
ingestion period (by two-way ANOVA)
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throughout the study. As the only difference between
the active and placebo beverages was the presence of
MHE, the results of our study indicate that ingestion of
MHE reduces body fat in healthy subjects with a BMI of
25 to below 30 kg/m2, while changes in energy intake
and physical activity can be ruled out to have influenced
the results.
VFA, TFA and SFA decreased as compared to the
baseline value (0 w) not only in the active group but also
in the placebo group. The reason for the reduction of
VFA, TFA and SFA in the placebo group is unclear at
the present time. One possibility is that participation in
the study itself may affect the metabolic state of the sub-
jects unconsciously. Indeed, it has been previously re-
ported that the mean values of body fat and body weight
in the placebo group decreased as compared to the base-
line value (0 w) [23, 24], similar to our study. In
addition, seasonal variation may affect VFA, TFA andTable 5 Change in circulatory parameters
Parameter Group Ingestion period
0 w 4 w
SBP (mmHg) A 119.9 (1.3) 120.7 (1.4)
P 120.3 (1.2) 120.9 (1.3)
DBP (mmHg) A 71.2 (1.1) 72.2 (0.9)
P 72.8 (0.9) 73.3 (1.0)
Pulse rate (bpm) A 70.0 (0.9) 71.5 (0.9)
P 72.4 (0.9) 73.3 (0.9)
Data are expressed as means (SEM). A, Active group (n = 94); P, Placebo group (n =
#P < 0.05 vs. Placebo group. *P < 0.05 vs. 0 wSFA in the placebo group, because seasonal variations of
body weight have been described [25, 26].
Previously, it has been reported that the 12-week mini-
mum effective dose of iso-α-acids needed to reduce VFA
significantly as compared to placebo for subjects with
prediabetes is 48 mg per day [11]. However, MHE does
not contain detectable amounts of iso-α-acids, indicative
that the anti-obesity effect of MHE is caused by compo-
nents other than iso-α-acids. The solid content of the
MHE used in this study contained 18.3% of MHBA. We
have reported that MHBA ameliorates diet-induced body
fat accumulation in rodents [18]. Moreover, studies in
rodents suggested that MHBA and MHE with the same
amount of MHBA have an equivalent effect on body fat
reduction (unpublished data). Hence, we speculate that
the effect of MHE on body fat reduction observed in this
study is mainly due to MHBA.
Because obesity occurs when energy intake exceeds
energy expenditure, inhibition of energy intake orFollow-up period
8 w 12 w 16 w
120.0 (1.2) 119.2 (1.2) 120.5 (1.2)
118.9 (1.2) 120.3 (1.3) 122.1 (1.2)*
71.9 (0.9) 71.7 (1.0) 72.3 (1.0)
72.1 (0.8) 72.8 (0.9) 73.5 (1.0)
* 69.1 (0.9)# 69.9 (0.9)# 69.9 (1.0)#
71.9 (0.8) 73.1 (0.9) 72.8 (0.9)
94)
Table 6 Change in blood chemistry parameters (liver function)
Parameter Sex Reference
range
Group Ingestion period Follow-up period
0 w 4 w 8 w 12 w 16 w
TP (g/dL) 6.5-8.2 A 7.30 (0.03) 7.27 (0.04) 7.23 (0.03)* 7.26 (0.03) 7.30 (0.03)
P 7.29 (0.03) 7.22 (0.03)* 7.28 (0.04) 7.28 (0.04) 7.31 (0.04)
Alb (g/dL) 3.7-5.5 A 4.46 (0.02) 4.43 (0.02) 4.42 (0.02)* 4.43 (0.02)* 4.48 (0.02)
P 4.50 (0.02) 4.46 (0.02)* 4.48 (0.02) 4.48 (0.03) 4.54 (0.02)*
T-Bil (mg/dL) 0.3-1.2 A 0.70 (0.03) 0.72 (0.03) 0.68 (0.03) 0.68 (0.03) 0.68 (0.03)
P 0.74 (0.03) 0.72 (0.03) 0.69 (0.03) 0.71 (0.03) 0.67 (0.03)**
AST (U/L) 10-40 A 21.1 (0.6) 20.5 (0.6)* 21.2 (0.7) 21.5 (0.9) 22.5 (0.8)*
P 20.9 (0.6) 20.7 (0.7) 21.3 (0.9) 21.4 (0.8) 21.4 (0.5)
ALT (U/L) 5-45 A 23.7 (1.3) 22.0 (1.3)** 23.0 (1.3) 23.3 (1.6) 25.0 (1.7)
P 22.2 (1.4) 21.0 (1.1) 24.1 (1.8) 23.5 (1.5) 22.5 (1.0)
LDH (U/L) 120-245 A 172.4 (2.5) 178.9 (2.8)** 174.9 (2.9) 179.1 (3.5)** 178.8 (3.7)*
P 175.5 (3.6) 179.3 (3.1) 175.6 (3.3) 173.3 (2.7) 174.1 (2.8)
ALP (U/L) 104-338 A 199.4 (5.3) 199.7 (5.4) 198.4 (5.3) 197.8 (5.1) 200.7 (5.4)
P 190.2 (5.5) 187.7 (5.5) 193.6 (5.6) 195.6 (5.9)* 197.5 (6.0)**
γ-GTP (U/L) M ≤79 A 37.7 (3.8) 36.1 (3.6) 37.6 (4.0) 37.0 (4.0) 38.9 (3.9)
P 39.7 (5.2) 39.6 (4.3) 43.2 (5.6) 41.0 (5.1) 40.7 (3.8)
F ≤48 A 24.7 (2.2)# 23.2 (1.7) 24.8 (2.3) 23.8 (2.0) 26.8 (2.5)
P 19.7 (1.3) 19.2 (1.2) 21.5 (1.6)* 20.7 (1.4) 21.6 (2.0)
Data are expressed as means (SEM). A, Active group (n = 94); P, Placebo group (n = 94). M, Male; F, Female
#P < 0.05 vs. Placebo group. *P < 0.05, **P < 0.01 vs. 0 w
Table 7 Change in blood chemistry parameters (lipids and glucose)
Parameter Sex Reference
range
Group Ingestion period Follow-up period
0 w 4 w 8 w 12 w 16 w
TC (mg/dL) 150-219 A 205.1 (3.6) 202.8 (3.5) 203.5 (3.5) 203.1 (3.6) 207.4 (3.8)
P 197.6 (3.7) 194.4 (3.5) 197.1 (3.7) 198.2 (3.7) 200.7 (3.8)*
LDL-C (mg/dL) 70-139 A 128.7 (3.3) 126.8 (3.2) 126.6 (3.2) 124.9 (3.3)* 128.7 (3.4)
P 121.5 (3.2) 118.1 (3.2)* 121.4 (3.4) 119.6 (3.3) 123.1 (3.4)
HDL-C (mg/dL) M 40-80 A 52.5 (1.7) 50.1 (1.5)** 50.8 (1.6)* 52.3 (1.6) 53.9 (1.7)
P 51.2 (1.6) 50.4 (1.9) 50.1 (1.9) 52.4 (1.9) 54.0 (1.8)**
F 40-90 A 56.4 (1.4) 55.1 (1.4)* 55.0 (1.5) 57.2 (1.4) 57.6 (1.5)
P 55.9 (1.4) 54.3 (1.4)** 55.5 (1.5) 57.1 (1.6) 57.3 (1.5)
TG (mg/dL) 50-149 A 106.2 (8.5) 113.0 (8.3) 123.9 (11.9)** 113.1 (9.9) 111.4 (8.0)
P 112.3 (7.7) 116.8 (7.6) 105.9 (5.6) 113.8 (7.0) 112.5 (6.7)
PL (mg/dL) 150-250 A 218.3 (3.2) 215.1 (2.9) 217.1 (3.1) 215.2 (3.2) 219.9 (3.3)
P 212.5 (3.0) 210.7 (3.0) 209.7 (2.9) 212.0 (3.0) 214.7 (2.8)
FFA (mEq/L) 0.10-0.81 A 0.539 (0.019) 0.625 (0.025)** 0.524 (0.021) 0.545 (0.022) 0.563 (0.019)
P 0.542 (0.021) 0.592 (0.023) 0.545 (0.020) 0.531 (0.019) 0.523 (0.019)
Glucose (mg/dL) 70-109 A 93.4 (0.9) 94.1 (0.9) 93.8 (0.9) 92.4 (0.9) 94.4 (1.0)
P 93.7 (1.0) 93.2 (1.0) 92.8 (1.0) 92.4 (1.0)* 94.6 (1.1)
Data are expressed as means (SEM). A, Active group (n = 94); P, Placebo group (n = 94). M, Male; F, Female
*P < 0.05, **P < 0.01 vs. 0 w
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Table 8 Change in blood chemistry parameters (kidney function and electrolyte)
Parameter Sex Reference
range
Group Ingestion period Follow-up period
0 w 4 w 8 w 12 w 16 w
UA (mg/dL) M 3.6-7.0 A 6.37 (0.15) 6.38 (0.17) 6.39 (0.14) 6.43 (0.16) 6.35 (0.16)
P 6.36 (0.17) 6.40 (0.18) 6.58 (0.17) 6.41 (0.18) 6.29 (0.14)
F 2.7-7.0 A 5.09 (0.13) 4.96 (0.14) 5.07 (0.12) 4.98 (0.15) 5.05 (0.13)
P 5.18 (0.14) 5.09 (0.14) 5.18 (0.14) 5.13 (0.14) 5.13 (0.14)
BUN (mg/dL) 8.0-20.0 A 13.65 (0.37) 13.58 (0.37) 13.12 (0.38) 12.67 (0.33)** 13.23 (0.30)
P 13.72 (0.35) 13.28 (0.35) 13.31 (0.38) 12.80 (0.30)** 13.32 (0.30)
Cre (mg/dL) M 0.65-1.09 A 0.816 (0.015) 0.811 (0.014) 0.809 (0.014) 0.791 (0.014)** 0.804 (0.013)
P 0.833 (0.019) 0.828 (0.019) 0.839 (0.020) 0.820 (0.019) 0.826 (0.021)
F 0.46-0.82 A 0.619 (0.014) 0.610 (0.015) 0.618 (0.015) 0.597 (0.013)* 0.619 (0.015)
P 0.629 (0.014) 0.617 (0.013) 0.625 (0.013) 0.606 (0.012)* 0.617 (0.012)
Na (mEq/L) 135-145 A 140.5 (0.2)## 140.6 (0.2) 140.5 (0.2)# 140.8 (0.2) 140.6 (0.2)
P 141.3 (0.2) 141.0 (0.2) 141.1 (0.2) 140.9 (0.2) 141.0 (0.2)
Cl (mEq/L) 98-108 A 103.9 (0.2) 103.8 (0.2) 104.0 (0.2) 103.8 (0.2) 103.6 (0.2)
P 104.1 (0.2) 104.1 (0.2) 104.2 (0.2) 103.9 (0.2) 103.8 (0.2)
K (mEq/L) 3.5-5.0 A 4.18 (0.03)# 4.08 (0.02)** 4.16 (0.03) 4.14 (0.03) 4.18 (0.03)
P 4.11 (0.03) 4.05 (0.03) 4.10 (0.03) 4.11 (0.02) 4.16 (0.02)*
Ca (mg/dL) 8.6-10.2 A 9.38 (0.03) 9.37 (0.04) 9.34 (0.04) 9.36 (0.03) 9.39 (0.03)
P 9.41 (0.04) 9.34 (0.04)* 9.40 (0.04) 9.41 (0.04) 9.41 (0.03)
Mg (mg/dL) 1.7-2.6 A 2.21 (0.02) 2.21 (0.01) 2.18 (0.01)* 2.19 (0.01) 2.19 (0.01)
P 2.20 (0.02) 2.22 (0.02) 2.21 (0.02) 2.20 (0.02) 2.20 (0.02)
Data are expressed as means (SEM). A, Active group (n = 94); P, Placebo group (n = 94). M, Male; F, Female
#P < 0.05, ##P < 0.01 vs. Placebo group. *P < 0.05, **P < 0.01 vs. 0 w
Table 9 Change in blood chemistry parameters (iron metabolism)
Parameter Sex Reference
range
Group Ingestion period Follow-up period
0 w 4 w 8 w 12 w 16 w
Fe (μg/dL) M 60-210 A 107.7 (5.0) 116.6 (6.3) 101.6 (4.4) 110.1 (5.4) 112.9 (6.7)
P 112.7 (5.6) 110.9 (5.6) 102.3 (5.0) 104.5 (5.2) 101.8 (5.0)
F 50-170 A 94.3 (4.8) 89.8 (4.6)# 94.1 (4.5) 86.1 (4.9)## 98.0 (4.8)
P 102.8 (4.9) 103.3 (5.0) 97.7 (5.3) 108.9 (5.3) 98.0 (5.4)
TIBC (μg/dL) M 250-410 A 323.7 (4.3) 317.7 (5.1)* 315.3 (4.2)** 319.4 (4.3)* 322.8 (4.4)
P 332.4 (5.4) 327.5 (4.8)* 326.2 (5.6)* 325.6 (5.3)* 329.4 (4.9)
F 250-460 A 341.7 (6.7) 331.9 (6.0)** 335.6 (6.5)* 333.3 (6.5)** 336.1 (6.3)
P 334.2 (6.1) 328.5 (5.5)* 334.1 (6.5) 332.9 (6.4) 336.7 (6.5)
UIBC (μg/dL) M 120-330 A 216.0 (5.9) 201.1 (6.8)* 213.7 (5.5) 209.3 (5.6) 210.0 (6.5)
P 219.8 (6.9) 216.7 (7.2) 223.9 (7.6) 221.2 (7.0) 227.6 (6.2)
F 110-425 A 247.4 (9.0) 242.2 (8.7) 241.5 (9.3) 247.2 (9.3) 238.1 (8.8)
P 231.3 (8.3) 225.1 (7.6) 236.4 (8.6) 224.0 (9.3) 238.7 (8.7)
Ferritin (ng/mL) M 21-282 A 147.76 (8.63) 151.39 (9.24) 147.35 (8.80) 146.59 (9.03) 150.44 (9.45)
P 137.97 (12.51) 142.62 (14.06) 143.55 (13.20) 145.89 (13.65) 143.39 (14.07)
F 5-157 A 51.71 (6.56) 49.91 (6.23) 50.46 (6.67) 54.47 (7.36) 54.44 (6.82)
P 48.63 (4.32) 45.86 (4.07) 49.63 (4.30) 51.02 (4.54) 49.55 (4.41)
Data are expressed as means (SEM). A, Active group (n = 94); P, Placebo group (n = 94). M, Male; F, Female
#P < 0.05, ##P < 0.01 vs. Placebo group. *P < 0.05, **P < 0.01 vs. 0 w
Morimoto-Kobayashi et al. Nutrition Journal  (2016) 15:25 Page 10 of 13
Table 10 Change in hematological parameters
Parameter Sex Reference
range
Group Ingestion period Follow-up period
0 w 4 w 8 w 12 w 16 w
WBC (/μL) 3500-9700 A 6090.1 (157.0) 6423.4 (183.2)** 6188.5 (166.2) 6298.6 (188.2) 6288.3 (156.4)*
P 5986.3 (143.3) 6094.6 (157.6) 6011.3 (143.5) 6108.6 (156.2) 6230.1 (153.6)*
RBC (×104/μL) M 438-577 A 491.9 (4.7)# 489.2 (4.7) 487.6 (4.5)* 489.7 (5.1) 495.0 (4.8)
P 507.8 (4.6) 498.6 (4.8)** 500.2 (4.5)** 500.1 (4.8)** 504.1 (4.9)
F 376-516 A 449.4 (4.2) 446.7 (4.5) 445.7 (4.2) 449.2 (4.3) 451.6 (4.4)
P 447.3 (4.4) 444.8 (4.8) 446.8 (4.8) 447.1 (4.7) 452.6 (4.4)*
Hb (g/dL) M 13.6-18.3 A 15.25 (0.13) 15.20 (0.14) 15.18 (0.14) 15.26 (0.17) 15.44 (0.14)*
P 15.51 (0.13) 15.24 (0.14)** 15.34 (0.13)* 15.32 (0.14)* 15.43 (0.14)
F 11.2-15.2 A 13.36 (0.14) 13.34 (0.14) 13.33 (0.14) 13.41 (0.14) 13.50 (0.14)*
P 13.44 (0.14) 13.38 (0.15) 13.44 (0.15) 13.44 (0.14) 13.60 (0.13)*
Ht (%) M 40.4-51.9 A 45.67 (0.39) 45.59 (0.44) 44.89 (0.43)** 45.06 (0.51) 45.66 (0.41)
P 46.46 (0.38) 45.96 (0.42)* 45.12 (0.40)** 45.35 (0.33)** 45.60 (0.39)**
F 34.3-45.2 A 41.32 (0.36) 40.91 (0.38) 40.66 (0.38)** 40.57 (0.31)** 40.81 (0.36)*
P 41.38 (0.39) 41.00 (0.42) 40.84 (0.43)** 40.63 (0.39)** 41.17 (0.37)
Plt (×104/μL) 14.0-37.9 A 25.95 (0.54) 26.06 (0.58) 26.02 (0.54) 25.94 (0.55) 26.74 (0.55)**
P 26.33 (0.59) 26.62 (0.60) 26.67 (0.63) 26.64 (0.59) 27.15 (0.61)**
Data are expressed as means (SEM). A, Active group (n = 94); P, Placebo group (n = 94). M, Male; F, Female
#P < 0.05 vs. Placebo group. *P < 0.05, ** P < 0.01 vs. 0 w
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an important target for preventing obesity [27]. Some
food ingredients have been reported to modulate energy
intake and energy expenditure in humans, for example,
lipid absorption inhibition by indigestible dextrin, and
energy expenditure acceleration by capsinoids [28–30].
In addition, bitter tastants have been reported to modu-
late the energy intake by regulating the appetite via
ghrelin secretion in mice [31], and by regulating sati-
ation during oral nutrient ingestion via altered gastro-
intestinal motility in humans [32]. In this study,
ingestion of MHE did not alter energy intake during the
ingestion period, and the time of MHE ingestion was
not limited, like at mealtime. These results suggest that
the anti-obesity effect of MHE may be induced by en-
ergy expenditure acceleration rather than energy intake
inhibition, by controlling appetite and lipid absorption.
Indeed, we have reported that MHBA enhances thermo-
genesis in BAT via activation of sympathetic nerve activ-
ity innervating BAT in rodents [18]. It has also been




0 w 4 w
Urine pH 4.8-7.5 A 5.92 (0.07) 5.8
P 5.89 (0.06) 5.7
Data are expressed as means (SEM). A, Active group (n = 94); P, Placebo group (n =plays a role in maintaining body weight [20, 21], and
BAT activity in humans is controlled by the sympathetic
nervous system, as observed in rodents [33]. As one of
the food ingredients modulating BAT activity, extract of
Kaempferia parviflora, a member of the ginger family,
has been reported to increase energy expenditure
through the activation of BAT in mice and humans [34,
35]. Hence, enhancement of thermogenesis in BAT may
contribute to the body fat reduction effect of MHE in
this study. On the one hand, MHBA at the concentra-
tion in the active beverage in this study (35 mg/350 mL)
did not cause a bitter sensation in the oral cavity because
its dose was too low to sense bitterness. On the other
hand, it has been reported that bitter taste receptors are
present not only in taste buds on the tongue but also in
endocrine cells of the gastrointestinal tract (GI tract)
[36]. On the binding of bitter tastants to bitter taste re-
ceptors in the GI tract, hormones or neurotransmitters
are released that can communicate with the brain and
have a role in the regulation of energy and glucose
homeostasis [36]. We have reported that MHBA inducesFollow-up period
8 w 12 w 16 w
1 (0.07) 5.91 (0.07) 5.90 (0.07) 5.79 (0.07)
9 (0.06) 5.73 (0.06)* 5.88 (0.06) 5.85 (0.06)
94). *P < 0.05 vs. 0 w
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gastric cavity in rodents [18]. This suggests that bitter
taste receptors in the endocrine cells of the GI tract
might be involved in the mechanism underlying the
anti-obesity effect of MHBA. In future work, intentional
dosing studies will be needed to identify the active com-
ponents and reveal the anti-obesity mechanism of MHE
in detail.
Obesity leads to metabolic disorders such as hyperten-
sion, diabetes mellitus and atherosclerosis, which are risk
factors for coronary artery disease [1–3]. Many studies
have reported that body fat distribution has a close rela-
tionship with the occurrence of metabolic disorders, and
an excess of abdominal fat, especially intra-abdominal
visceral fat, leads to these disorders, irrespective of body
weight [37–39]. Accordingly, it is very important to re-
duce body fat, especially visceral fat for the prevention
of metabolic disorders. Our results indicate that MHE
reduces TFA by reducing mainly VFA. Therefore, MHE
may be useful for preventing obesity as well as reducing
the risk of metabolic disorders and coronary artery dis-
ease. Adipomyokines such as leptin, adiponectin and iri-
sin, and gut hormones such as ghrelin and glucagon-like
peptide-1, are known to play an important role in energy
homeostasis [40, 41]. It is presumed that an imbalance
in the circulating levels of some of these hormones is re-
lated to metabolic disorders [40, 42], and the beneficial
effect of food intervention on these profiles has been re-
ported. For example, it has been reported that continual
ingestion of pistachio nuts and catechin increase adipo-
nectin level in, respectively, subjects with metabolic syn-
drome and subjects with type 2 diabetes [43, 44].
Intensive studies on whether MHE affects these hor-
mone levels will provide valuable information concern-
ing the effect of MHE on metabolic disorders.
At the doses used in this study, MHE did not induce
abnormal changes in hepatic function, renal function or
electrolytes. Body weight and values of all circulatory pa-
rameters were within the range of physiological vari-
ation, and values of all parameters for blood chemistry,
hematology and urinalysis were within the reference
ranges. All adverse events reported during the study
period were judged to be mild and to be unrelated to
the test beverages by the site investigators. Thus, it may
be assumed that continual ingestion of MHE for 12
weeks is safe. In addition, the effects of MHE on redu-
cing VFA, TFA and body fat ratio were mitigated at the
end of the follow-up period, indicating that continual in-
gestion of MHE is necessary in order to maintain the
anti-obesity effects of MHE.
A potential limitation of the study was the relative
short duration, so that any long-term effects of MHE in-
gestion remain unknown. As the difference in VFA and
TFA between the active and placebo groups increasedover time and did not plateau by the end of the period
of test-beverage ingestion, it is possible that the benefits
offered by MHE would increase over a longer period of
ingestion.
Conclusions
This study revealed that continual ingestion of MHE re-
duces body fat in healthy humans with a BMI of 25 or
more and less than 30 kg/m2 without the need for any
lifestyle change. Intake of MHE (35 mg as the amount of
MHBA) per day was sufficient to achieve this effect.
Therefore, MHE could be a useful and safe tool to pre-
vent obesity and related metabolic disorders.
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